Filip mussen (12 risultati)

Hardcover. Condizione: Fine. 1st Edition. Fine condition. Looks unread.

Hardcover. Condizione: Good+. 1st Edition. Hardcover, x + 294 pages, NOT ex-library. Interior is very good: clean and bright throughout, with unmarked text, free of inscriptions and stamps, firmly bound. Gently shelfworn boards show two tiny closed edge-nicks (upper corner of the front panel), creases to the lower spine. Issued without a dust jacket. …

Condizione: New.

Condizione: New.

Hardcover. Condizione: New. In shrink wrap. Looks like an interesting title.

Condizione: As New. Unread book in perfect condition.

Condizione: New. pp. x + 294 Index 1st Edition.

Condizione: New. pp. x + 294 Illus.

Condizione: New. Brand new! Please provide a physical shipping address.

Condizione: New. Establishes the criteria required to assess benefit-risk in general and reviews the current practice of benefit-risk assessment by drug regulatory authorities and the pharmaceutical industry. Outlines how the new MCDA model was developed and evaluated, and discusses the implications of its implementation into the practice of drug evaluation. Num Pages: 304 pages, Illustrations. BIC Classification: MBGR; MMG. Category: (P) Professional & Vocational. Dimension: 252 x 174 x 21. Weight in Grams: 670. . 2010. 1st Edition. Hardcover. . . . .…

Condizione: New. Establishes the criteria required to assess benefit-risk in general and reviews the current practice of benefit-risk assessment by drug regulatory authorities and the pharmaceutical industry. Outlines how the new MCDA model was developed and evaluated, and discusses the implications of its implementation into the practice of drug evaluation. Num Pages: 304 pages, Illustrations. BIC Classification: MBGR; MMG. Category: (P) Professional & Vocational. Dimension: 252 x 174 x 21. Weight in Grams: 670. . 2010. 1st Edition. Hardcover. . . . . Books ship from the US and Ireland.…

Buch. Condizione: Neu. Neuware - Benefit-risk assessment is at the centre of the approval process for every new medicine. The ability to assess the risks of a new medicine accurately and to balance these against the benefits the medicine could bring is critical for every regulatory authority and pharmaceutical company. Despite this there are very few tried and tested evaluative models currently available.The authors of this book have developed a new, pioneering tool for the assessment of benefits and risks for new medicines in development. This model utilises a multi-criteria decision analysis which involves selecting, scoring and weighting key benefit and risk attributes and leads to an overall appraisal of benefits and risks of medicines.Benefit-Risk Appraisal of Medicines establishes the background and criteria required to assess benefit and risk in general and reviews the current practices by regulatory authorities and the pharmaceutical industry, including those models currently available. It outlines the development and evaluation of the authors' new model and analyses the implications of its implementation.\* Describes an innovative, systematic model which leads to transparent and responsible benefit-risk decision making\* Contributes important ideas to the debate on benefit-risk appraisal\* Provides a future framework for benefit-risk appraisal of medicinesBenefit-Risk Appraisal of Medicines covers the entire process from the discovery of new medicines to their marketing and is ideal for all those who work in the pharmaceutical industry and regulatory authorities, as well as post-graduate students of pharmaceutical medicine and clinical pharmacology.…